ISIN:DE000A2GS5D8

EQS-News: Dermapharm Holding SE fulfils all expectations despite multiple macroeconomic challenges

Retrieved on: 
Mittwoch, April 10, 2024
Annual, Tax, Aggression, COVID-19, Euromed, Supervision, Acquisition, Management, Annual report, Depreciation, PPA, Parallel, Lithium

Grünwald, 28 March 2024 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, today published its full Annual Report 2023.

Key Points: 
  • Grünwald, 28 March 2024 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, today published its full Annual Report 2023.
  • Despite a difficult macroeconomic environment, Dermapharm succeeded in maintaining its growth trajectory and hitting the upper end of the guidance range in 2023.
  • "In addition to the end of the boom phase associated with vaccine production, 2023 was also shaped by various other macroeconomic and geopolitical challenges.
  • The Annual General Meeting of Dermapharm Holding SE will take place on 27 June 2024.

EQS-News: Dermapharm Holding SE hits upper end of guidance range for adjusted EBITDA, primarily due to steadily growing international presence in branded business

Retrieved on: 
Mittwoch, April 10, 2024
Annual, Annual report, Tax, BioNTech, Coronavirus, Inflammation, Acquisition, Management, Dermatology, Depreciation, Pain, Growth, Parallel, Pharmaceutical industry

Dermapharm Holding SE hits upper end of guidance range for adjusted EBITDA, primarily due to steadily growing international presence in branded business

Key Points: 
  • Dermapharm Holding SE hits upper end of guidance range for adjusted EBITDA, primarily due to steadily growing international presence in branded business
    The issuer is solely responsible for the content of this announcement.
  • » Adjusted consolidated EBITDA margin: 27.3%
    Grünwald, 14 March 2024 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today publishes its unaudited preliminary consolidated figures (IFRS) for financial year 2023.
  • Adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) declined by 13.8% to EUR 310.2 million (prior-year period: EUR 359.8 million).
  • We exceeded our guidance for consolidated revenue and reached the upper end of the forecast range for adjusted EBITDA.

EQS-News: Dermapharm Holding SE erreicht das obere Ende der Prognose des bereinigten Konzern-EBITDAs vor allem wegen stetig wachsender internationaler Präsenz im Markengeschäft

Retrieved on: 
Mittwoch, April 10, 2024
Holding, Produktion, Konzern, Umsatz, Ergebnis, Zins, Steuern, Abschreibung, Vorstand, Hauptversammlung, Dividende, Aktie, Prognose, Akquisition, Wachstum, Doktor, Synergie, Kooperation, Biontech, Segment, Hintergrund, Beendigung, Pandemie, Q1, Quartal, Produkt, Gesellschaft, Anfang, Betrag, Zahlung, Cent, Zahl

EQS-News: Dermapharm Holding SE builds on success in Q3 2023

Retrieved on: 
Samstag, Dezember 30, 2023
Tax, Depreciation, Supply, Growth, Management, Safety, Parallel, Annual report, Film industry

Consolidated revenue and EBITDA (adjusted) stay on course, climbing to EUR 866.6 million and EUR 243.8 million, respectively

Key Points: 
  • Consolidated revenue and EBITDA (adjusted) stay on course, climbing to EUR 866.6 million and EUR 243.8 million, respectively
    Grünwald, 15 November 2023 – Dermapharm Holding SE ("Dermapharm"), an innovative rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today publishes its results for the first nine months of 2023.
  • The Group increased revenue by 18.0% to EUR 866.6 million in the reporting period (prior-year period: EUR 734.3 million).
  • 9M 2023 adjusted EBITDA amounts to EUR 183.8 million (prior-year period: EUR 216.9 million).
  • Accordingly, adjusted EBITDA also saw a pronounced increase of 154.2% to EUR 63.3 million (prior-year period: EUR 24.9 million).

EQS-News: Dermapharm Holding SE publishes H1 2023 financial report, confirms outlook for 2023 overall

Retrieved on: 
Dienstag, August 29, 2023
Friedrichsdorf, Tax, EBITDA, The Board of Management of the Chinese Permanent Cemeteries, Parallel, Depreciation, Rare-earth element, Film industry, EUR

Dermapharm Holding SE publishes H1 2023 financial report, confirms outlook for 2023 overall

Key Points: 
  • Dermapharm Holding SE publishes H1 2023 financial report, confirms outlook for 2023 overall
    The issuer is solely responsible for the content of this announcement.
  • Dermapharm Holding SE publishes H1 2023 financial report, confirms outlook for 2023 overall
    Consolidated revenue and EBITDA (adjusted) stay on course, climbing year on year to EUR 582.1 million and EUR 168.0 million, respectively
    Grünwald, 29 August 2023 – Dermapharm Holding SE ("Dermapharm"), an innovative and rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today published its report for the first half of 2023 and confirmed the preliminary consolidated figures (IFRS).
  • According to the finalised and reviewed IFRS consolidated figures, Dermapharm lifted its revenue in H1 2023 by 23.6% to EUR 582.1 million (previous year: EUR 471.1 million).
  • H1 2023 adjusted EBITDA amounts to EUR 127.3 million (previous year: EUR 134.6 million).

EQS-News: Dermapharm Holding SE: First half of 2023 is a success despite the challenging market environment

Retrieved on: 
Dienstag, August 22, 2023
BioNTech, Tax, Inflammation, Marketing, Pain, EUR, Dermatology, EBITDA, Board of Management St. Molaga's National School v The Secretary General of the Department of Education and Science, Parallel, Depreciation, Growth, Pharmaceutical industry

Dermapharm successfully maintains its growth trend as planned in the first six months of financial year 2023.

Key Points: 
  • Dermapharm successfully maintains its growth trend as planned in the first six months of financial year 2023.
  • "Despite a challenging market environment, our business has performed very successfully from an operational standpoint in the first half of 2023.
  • The positive performance in the first half of 2023 laid a good foundation for the further course of the business.
  • Dermapharm will publish its final figures for the first half of 2023 along with its complete 2023 half-yearly financial report on 29 August 2023.